Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Bridging the Gap between the Clinical and Regulatory Use of...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 7490

Special Issue Editors

Dr. Eduardo Anitua

E-Mail Website
Guest Editor
Department Head, Eduardo Anitua Foundation, Vitoria; Private Practice in Oral Implantology, Vitoria, Spain
Interests: regenerative medicine; plasma rich in growth factors; PRGF; growth factors; cell therapy; evidence-based clinical practice; implant dentistry
Dr. Mohammad Hamdan Alkhraisat

E-Mail Website
Guest Editor
1. Regenerative Medicine Department, BTI Biotechnology Institute, 01005 Vitoria, Spain
2. Clinical Research, University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01005 Vitoria, Spain
Interests: oral medicine; implant dentistry; biomaterials; regenerative medicine; PRGF
Dr. Sabino Padilla

E-Mail Website
Guest Editor
1. University Institute for Regenerative Medicine and OralImplantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain
2. BTI Biotechnology Institute, Vitoria, Spain
Interests: Evolution; Coagulation; Haemostasia; Platelets: Platelet-rich plasma; Wound healing; Epigenetics; minimally-invasive surgery; Orthopaedics

Special Issue Information

Dear Colleagues,

Platelet-rich plasma (PRP) therapies have been attracting great attention in both the research and clinical community. However, the field faces important challenges at the basic, clinical, and regulatory frameworks. These three fields are progressing at a different pace, thereby generating a gap that in certain occasions is difficult to bridge effectively and efficiently. An evidence-based approach and appropriate regulatory framework would ensure both patient safety and the consolidation of current treatments and development of future applications. At the same time, quality studies are needed to promote the safe advancement of these types of biologic therapies.

Manuscripts are welcome to be submitted to cover the topics of platelet-rich plasma therapies, including in vitro research, preclinical in vivo, clinical studies or regulatory issues regarding the use of PRPs. However, the topics of interest are not limited to these. This issue aims to put in the same space and time coordinated basic, translational, and clinical research together with a regulatory/ethical overview in an effort to approximate the needs and bridge the gap.

Dr. Eduardo Anitua
Dr. Mohammad Alkhraisat
Dr. Sabino Padilla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Advanced cell therapy
  • Platelet-rich plasma
  • Wound healing
  • Stem cells
  • Patient care
  • Medicine
  • Platelets
  • Plasma
  • Patient screening
  • Blood processing

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

17 pages, 3600 KiB  
Article
Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum
by Eduardo Anitua, Francisco Muruzabal, Ander Pino, Roberto Prado, Mikel Azkargorta, Felix Elortza and Jesús Merayo-Lloves
Int. J. Mol. Sci. 2021, 22(22), 12176; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212176 - 10 Nov 2021
Cited by 9 | Viewed by 1935
Abstract
Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, [...] Read more.
Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, different blood-derived products like autologous serum (AS) and plasma rich in growth factors (PRGF) have been developed for the treatment of diverse ocular pathologies. However, scarce studies have been carried out to analyze the differences between both types of blood-derived products. In the present study, blood from three healthy donors was drawn and processed to obtain AS and PRGF eye drops. Then, human corneal stromal keratocytes (HK) were treated with PRGF or undiluted AS. Proteomic analysis was carried out to analyze and characterize the differential protein profiles between PRGF and AS, and the differentially expressed proteins in HK cells after PRGF and AS treatment. The results obtained in the present study show that undiluted AS induces the activation of different pathways related to an inflammatory, angiogenic, oxidative stress and scarring response in HK cells regarding PRGF. These results suggest that PRGF could be a better alternative than AS for the treatment of ocular surface disorders. Full article
(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

28 pages, 919 KiB  
Review
Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization
by Eduardo Anitua, Mar Zalduendo, Maria Troya, Mohammad H. Alkhraisat and Leticia Alejandra Blanco-Antona
Int. J. Mol. Sci. 2022, 23(12), 6552; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23126552 - 11 Jun 2022
Cited by 6 | Viewed by 2090
Abstract
There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed [...] Read more.
There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed and Web of Science databases until June 2021. Forty-one studies completed the selection criteria. The composition of PRP was completely reported in less than 30% of the studies. PRP has been used as PRP-derived supernatant or non-activated PRP. Two ranges could be identified for platelet concentration, the first between 0.14 × 106 and 0.80 × 106 platelets/µL and the second between 1.086 × 106 and 10 × 106 platelets/µL. Several studies have pooled PRP with a pool size varying from four to nine donors. The optimal dose for the PRP or PRP supernatant is 10%. PRP or PRP-derived supernatants a have positive effect on MSC colony number and size, cell proliferation, cell differentiation and genetic stability. The use of leukocyte-depleted PRP has been demonstrated to be a feasible alternative to xenogeneic sera. However, there is a need to improve the description of the PRP preparation methodology as well as its composition. Several items are identified and reported to create guidelines for future research. Full article
(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

11 pages, 4965 KiB  
Case Report
Plasma Rich in Growth Factors in the Treatment of Endodontic Periapical Lesions in Adult Patients: Case Reports
by Katarzyna Machut, Agata Zoltowska, Elzbieta Pawlowska and Marcin Derwich
Int. J. Mol. Sci. 2021, 22(17), 9458; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179458 - 31 Aug 2021
Cited by 6 | Viewed by 2475
Abstract
Platelet-rich fibrin (PRF) is an autologous blood concentrate obtained without anticoagulants by centrifugation of patients’ peripheral venous blood. PRF is considered to enhance the formation of new bone. The aim of this manuscript was to present two case reports of permanent teeth with [...] Read more.
Platelet-rich fibrin (PRF) is an autologous blood concentrate obtained without anticoagulants by centrifugation of patients’ peripheral venous blood. PRF is considered to enhance the formation of new bone. The aim of this manuscript was to present two case reports of permanent teeth with closed apexes with periapical lesions, treated endodontically with the use of PRF. The root canals were mechanically cleaned and shaped with NiTi files and irrigated with 5.25% sodium hypochlorite (NaOCl), 40% citric acid (CA), and triple distillated water. Before the canal systems were obturated, A-PRF was used as a scaffold and was placed below the cementodentinal junction with hand pluggers. Cone beam computerized tomography (CBCT) was used to assess the resolutions of periapical radiolucencies. After 6 months, the measurements of both periapical lesions were significantly reduced. Although the performed root canal treatments (RCTs) can definitely be recognized as successful, it must be emphasized that mechanical shaping and cleaning of the root canals with special disinfecting solutions significantly affect the clinical efficacy of RCT. It seems impossible to state that PRF played a leading role in the healing process of the presented periapical lesions. Further studies must be performed to assess whether RCT of mature teeth with an additional PRF application is superior to RCT performed alone. Full article
(This article belongs to the Special Issue Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We?)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop